236. Pseudohypoparathyroidism
6 clinical trials, 4 drugs (DrugBank: 2 drugs), 20 drug target genes, 28 drug target pathways
Searched query = "Pseudohypoparathyroidism", "PHP", "PHP1a", "PHP1b", "PHP1c", "PHP2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04551170 (ClinicalTrials.gov) | July 13, 2020 | 9/9/2020 | Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old | Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism | Pseudohypoparathyroidism;Albright Hereditary Osteodystrophy;Pseudohypoparathyroidism Type 1a | Drug: Theophylline;Drug: Placebo | Vanderbilt University Medical Center | NULL | Recruiting | 2 Years | 12 Years | All | 34 | Phase 2 | United States |
| 2 | NCT04240821 (ClinicalTrials.gov) | May 22, 2020 | 21/1/2020 | Theophylline for Treatment of Pseudohypoparathyroidism | Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism | Pseudohypoparathyroidism;Pseudohypoparathyroidism Type 1a;Albright Hereditary Osteodystrophy | Drug: Theophylline ER | Ashley Shoemaker | NULL | Enrolling by invitation | 2 Years | 99 Years | All | 34 | Phase 2 | United States |
| 3 | NCT03718403 (ClinicalTrials.gov) | April 10, 2019 | 8/9/2017 | Effect of Theophylline in Pseudohypoparathyroidism | Effect of Theophylline in Pseudohypoparathyroidism | PHP Ia;PHP IB;Php1C | Drug: Theophylline | Massachusetts General Hospital | NULL | Not yet recruiting | 5 Years | 21 Years | All | 40 | Phase 4 | NULL |
| 4 | NCT03029429 (ClinicalTrials.gov) | September 1, 2018 | 18/1/2017 | Theophylline Treatment for Pseudohypoparathyroidism | Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism | Pseudohypoparathyroidism;Albright Hereditary Osteodystrophy | Drug: Theophylline;Drug: Placebos | Vanderbilt University Medical Center | Harvard University | Recruiting | 13 Years | 99 Years | All | 34 | Phase 2 | United States |
| 5 | NCT02463409 (ClinicalTrials.gov) | June 2015 | 20/5/2015 | Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy) | Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a | Pseudohypoparathyroidism Type 1a;Albright Hereditary Osteodystrophy | Drug: Theophylline | Vanderbilt University Medical Center | Massachusetts General Hospital | Completed | 10 Years | 21 Years | All | 6 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00497484 (ClinicalTrials.gov) | February 1995 | 5/7/2007 | Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia) | Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia) | Pseudohypoparathyroidism;Growth Hormone Deficiency, Dwarfism | Drug: recombinant human somatotropin | University of Milan | Eli Lilly and Company | Active, not recruiting | 1 Year | 18 Years | Both | N/A | Italy |